|1.||Vij, Ravi: 14 articles (11/2015 - 06/2011)|
|2.||Siegel, David S: 13 articles (10/2015 - 06/2012)|
|3.||Jagannath, Sundar: 11 articles (11/2015 - 06/2011)|
|4.||Wang, Michael: 10 articles (10/2015 - 06/2012)|
|5.||Jakubowiak, Andrzej J: 10 articles (10/2015 - 06/2012)|
|6.||Kirk, Christopher J: 9 articles (09/2014 - 05/2009)|
|7.||Stewart, A Keith: 8 articles (04/2015 - 11/2009)|
|8.||Lonial, Sagar: 8 articles (09/2014 - 06/2011)|
|9.||Orlowski, Robert Z: 8 articles (10/2013 - 11/2007)|
|10.||Niesvizky, Ruben: 6 articles (10/2015 - 01/2013)|
08/07/2014 - "Standard carfilzomib (20 mg/m(2) cycle 1, 27 mg/m(2) thereafter; 2- to 10-minute infusion) is safe and effective in relapsed or refractory multiple myeloma (R/RMM). "
01/01/2012 - "Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma."
10/01/2013 - "The mechanism of action, pharmacokinetics, and clinical efficacy of carfilzomib for the treatment of multiple myeloma."
04/01/2014 - "Single-agent carfilzomib has produced robust and durable responses in clinical trials and it has been approved in the US for treating relapsed and refractory multiple myeloma (MM). "
01/01/2014 - "In the pivotal Phase II study (PX-171-003-A1), carfilzomib 20/27 mg/m(2) provided durable responses in a heavily pretreated population with relapsed and refractory multiple myeloma (n=266), with an overall response rate of 22.9% and a median duration of response of 7.8 months. "
12/28/2014 - "In vivo, liposomal carfilzomib demonstrated significant tumor growth inhibition and dramatically reduced overall systemic toxicity compared to free carfilzomib. "
10/01/2013 - "A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors."
02/01/2015 - "Haematological cancer: ASPIRE for unprecedented benefit with carfilzomib in MM."
09/01/2014 - "Moreover, the combination treatment in an in vivo MM mouse model inhibited tumor burden compared with CC-292 alone; it also increased bone volume compared with carfilzomib alone. "
11/01/2013 - "In MCL-bearing SCID mice/primary MCL-bearing SCID-hu mice, intravenous administration of 5 mg/kg carfilzomib on days 1 and 2 for 5 weeks slowed/abrogated tumor growth and significantly prolonged survival. "
|3.||Peripheral Nervous System Diseases (PNS Diseases)
10/04/2012 - "Thirty-three patients (12.4%) experienced peripheral neuropathy, primarily grades 1 or 2. Thirty-three patients (12.4%) withdrew because of an AE. Durable responses and an acceptable tolerability profile in this heavily pretreated population demonstrate the potential of carfilzomib to offer meaningful clinical benefit. "
08/01/2012 - "The safety profile, specifically a lower incidence of peripheral neuropathy, efficacy in the high-risk setting, as defined cytogenetically, and the durability of responses indicate a great potential for carfilzomib as a promising therapy. "
12/01/2013 - "Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib."
01/01/2013 - "The current review spotlights the second generation proteasome inhibitors with special focus on the safety and efficacy of carfilzomib, an epoxyketone with lesser peripheral neuropathy, which exhibits irreversible proteasome inhibition. "
03/01/2013 - "Peripheral neuropathy is less common in patients receiving carfilzomib compared to bortezomib. "
|4.||Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)
11/01/2013 - "In vitro and in vivo therapeutic efficacy of carfilzomib in mantle cell lymphoma: targeting the immunoproteasome."
09/01/2011 - "Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo."
02/01/2015 - "In multiple myeloma and mantle cell lymphoma, treatment with the first-generation proteasome inhibitor, bortezomib, or the second-generation inhibitor, carfilzomib, has demonstrated significant therapeutic benefit in humans. "
12/01/2014 - "Interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib were examined in non-Hodgkin lymphoma (NHL) models, including diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and double-hit lymphoma cells. "
09/01/2011 - "Interactions between the proteasome inhibitor carfilzomib and the histone deacetylase (HDAC) inhibitors vorinostat and SNDX-275 were examined in mantle cell lymphoma (MCL) cells in vitro and in vivo. "
|5.||Hematologic Neoplasms (Hematological Malignancy)
11/15/2009 - "In a phase 1 trial evaluating the safety and efficacy of carfilzomib in relapsed or refractory hematologic malignancies, eight dose groups of three to six patients received 5 consecutive days of carfilzomib i.v. push at doses of 1.2, 2.4, 4, 6, 8.4, 11, 15, and 20 mg/m2 within 14-day cycles. "
09/01/2012 - "The objectives of this phase I study were to establish the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of escalating doses of carfilzomib in patients with relapsed or refractory hematologic malignancies. "
05/01/2011 - "In clinical studies carfilzomib has demonstrated substantial antitumor activity in hematologic malignancies while exhibiting a well-tolerated side-effect profile. "
11/15/2009 - "This is the first clinical use of carfilzomib that shows tolerability and clinical activity in multiple hematologic malignancies using consecutive-day dosing."
11/15/2009 - "A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies."
|1.||Proteasome Endopeptidase Complex (Proteasome)
|3.||lenalidomide (CC 5013)
|9.||benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone
|1.||Stem Cell Transplantation
|2.||Drug Therapy (Chemotherapy)
|3.||Renal Dialysis (Hemodialysis)